Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting

Zeitschrift fur Kardiologie

Volumn 92, Issue 12, 2003, Pages 1025-1028

  Scheller, B ^a   Schmitt, A ^a   Bohm M ^a   Nickenig, G ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Drug coated stents; Restenosis; Statin

Indexed keywords

ATORVASTATIN;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; INFLAMMATION; MORPHOMETRICS; NONHUMAN; RESTENOSIS; SWINE; TREATMENT FAILURE;

ADMINISTRATION, TOPICAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL DIVISION; CELL MOVEMENT; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY VESSELS; HEPTANOIC ACIDS; MUSCLE, SMOOTH, VASCULAR; PYRROLES; STENTS; SWINE;

EID: 1642544689     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-003-1022-4     Document Type: Article

References (20)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease (STRESS-Trial). N Engl J Med 331:496-501
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P (1994) A comparision of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease (BENESTENT-Trial). N Engl J Med 331:489-495
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780
4. Kuntz RE, Baim DS (2000) Prevention of coronary restenosis: the evolving evidence base for radiation therapy. Circulation 101:2130-2133
5. Suzuki T, Kopia G, Hayashi SI, Bailey LR, Llanos G, Wilensky R, Klugherz B, Papandreou G, Narayan P, Leon MB, Yeung A, Tio F, Tsao PS, Falotico R, Carter AJ (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193
6. Heldman AW, Cheng L, Jenkins GM et al (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289-2295
7. Costa MA, Sabate M, van der Giessen WJ et al (1999) Late coronary occlusion after intracoronary brachytherapy. Circulation 100:789-792
8. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau H, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney M, Lansky A, Stertzer S, Yock P, Fitzgerald P, for the SCORE Investigators (2002) 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth. Circulation 106:1788-1793
9. Laufs U, Marra D, Node K, Liao JK (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J Biol Chem 274(31):21926-21931
10. Werner N, Nickenig G, Laufs U (2002) Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 97(2):105-116
11. Schwartz RS, Huber KC, Murphy JG et al (1992) Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19: 267-274
12. Kornowski R, Hong MK, Tio FO et al (1998) In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31:224-230
13. Farb A, Sangiorgi G, Carter AJ et al (1999) Pathology of acute and chronic stenting in humans. Circulation 99:44-52
14. Mulder HJ, Bal ET, Jukema JW, Zwinderman AH, Schalij MJ, van Boven AJ, Bruschke AV (2000) Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 86(7):742-746
15. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM (2000) Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 85(8):962-968
16. Baumbach A, Herdeg C, Kluge M, Oberhoff M, Lerch M, Haase KH, Wolter C, Schröder S, Karsch KR (1999) Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Cath Card Int 47:102-106
17. Corsini et al (1999) Pharmacology & Therapeutics 84:413-428
18. Lafont A, Faxon D (1998) Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res 39(1):50-59
19. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman D, Virmani R, for the Consensus Committee (2002) Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106:1867-1873
20. Virmani R, Farb A, Kolodgie F (2002) Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz 27:1-6